Trinity Biotech (TRIB) Common Equity (2009 - 2025)

Trinity Biotech has disclosed Common Equity across 17 years of filings, most recently posting -$72.0 million for Q4 2025.

• Common Equity for Q4 2025 came in at -$72.0 million, down 104.6% year-over-year; the trailing twelve-month figure through Dec 2025 was -$72.0 million (down 104.6% YoY), and the FY2025 annual result was -$72.0 million, down 104.6% from the prior year.
• Common Equity came in at -$72.0 million for Q4 2025 at Trinity Biotech, down from -$49.5 million in the prior quarter.
• In the past five years, Common Equity ranged from a high of $15.8 million in Q2 2022 to a low of -$72.0 million in Q4 2025.
• The 5-year median for Common Equity is -$9.0 million (2023), against an average of -$15.6 million.
• Peak annual rise in Common Equity reached 3289.31% in 2022, while the deepest fall reached 4848.82% in 2022.
• Trinity Biotech's Common Equity stood at -$319000.0 in 2021, then tumbled by 582.13% to -$2.2 million in 2022, then slumped by 1000.6% to -$23.9 million in 2023, then plunged by 46.9% to -$35.2 million in 2024, then plunged by 104.6% to -$72.0 million in 2025.
• The last three Common Equity figures came in at -$72.0 million (Q4 2025), -$49.5 million (Q2 2025), and -$35.2 million (Q4 2024), per Business Quant data.